Table 3 Progression-free survival and response by time to relapse in ASPIRE and ENDEAVOR

From: Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

 

ASPIRE (1R1T subgroup)

ENDEAVOR (1R1T subgroup)

 

Early relapsers

Late relapsers

Early relapsers

Late relapsers

 

KRd (n=19)

Rd (n=19)

KRd (n=69)

Rd (n=59)

Kd (n=23)

Vd (n=28)

Kd (n=99)

Vd (n=110)

PFS

 Median PFS, months (95% CI)

15.2 (5.1–24.1)

9.3 (3.9–16.1)

33.5 (25.9–38.9)

24.3 (15.0–NE)

NE (7.1–NE)

8.0 (2.8–12.1)

NE (15.6–NE)

11.2 (8.8–NE)

 HR, KRd/Rd or Kd/Vd (95% CI)

0.751 (0.353–1.599)

 

0.718 (0.432–1.195)

 

0.357 (0.153–0.832)

 

0.479 (0.297–0.771)

 

 P-value (one-sided)

0.2279

 

0.0996

 

0.0065

 

0.0010

 

Overall response

 CR or better, n (%)

1 (5.3)

0

27 (39.1)

8 (13.6)

0

0

18 (18.2)

13 (11.8)

 VGPR or better, n (%)

13 (68.4)

7 (36.8)

56 (81.2)

30 (50.8)

12 (52.2)

5 (17.9)

63 (63.6)

45 (40.9)

 ORR (95% CI)

78.9 (54.4–93.9)

57.9 (33.5–79.7)

92.8 (83.9–97.6)

72.9 (59.7–83.6)

87.0 (66.4–97.2)

50.0 (30.6–69.4)

82.8 (73.9–89.7)

71.8 (62.4–80.0)

  1. Abbreviations: 1R1T, first relapse after frontline ASCT; ASCT, autologous stem cell transplantation; CI, confidence interval; CR, complete response; HR, hazard ratio; Kd, carfilzomib+dexamethasone; KRd, carfilzomib+lenalidomide+dexamethasone; NE, not estimable; ORR, overall response rate; PFS, progression-free survival; Rd, lenalidomide+dexamethasone; Vd, bortezomib+dexamethasone; VGPR, very good partial response. Includes patients who enrolled in study at first relapse post-ASCT. Early relapsers refers to patients relapsing <12 months post-ASCT. Late relapsers refers to patients relapsing ⩾12 months post-ASCT.
Back to article page